GPIIb-IIIa antagonists cause rapid disaggregation of platelets pre-treated with cytochalasin D. Evidence that the stability of platelet aggregates depends on normal cytoskeletal assembly

Platelets

Volumn 9, Issue 3-4, 1998, Pages 227-232

  May, J A ^a,c   Ratan, H ^a   Glenn, J R ^a   Losche W ^b   Spangenberg, P ^b   Heptinstall, S ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACTIN; ACTIN BINDING PROTEIN; ADENOSINE DIPHOSPHATE; ADRENALIN; ALPHA ACTININ; COLLAGEN; CYTOCHALASIN D; EDETIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; ILOPROST; MYOSIN;

CONFERENCE PAPER; CYTOSKELETON; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

EID: 0031809354     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537109876744     Document Type: Conference Paper

References (11)

1. Fox JEB. The platelet cytoskeleton. Thromb Haemostas 1993; 70: 884-93.
2. May JA, Heptinstall S, Spangenberg P. Changes in the composition of the platelet cytoskeleton in response to ADP: effects of MK-852 and ARL 66096. Blood Coag Fibrinol 1996; 7: 221-4.
3. May JA, Glenn JR, Spangenberg P, Heptinstall S. The composition of the platelet cytoskeleton following activation by ADP: effects of various agents that modulate platelet function. Platelets 1996; 7: 159-68.
4. Torti M, Festetics ET, Bertoni A, Sinigaglia F, Bulduini C. Agonist-induced actin polymerization is required for the irreversibility of platelet aggregation. Thromb Haemostas 1996; 76: 444-9.
5. Yuan AS, Hand EL, Hichens M, Olah TV, Barrish A, Fernandez-Metzler C, Gilbert JD. Determination of MK-852, a new fibrinogen receptor antagonist, in plasma and urine by radioimmunoassay. J Pharm Biomed Anal 1993; 11: 427-34.
6. Foster MR, Pike NB, Hornby EJ, Porter B, Eldred CD, Ross BC, Lumley P. GR144053, a potent and specific non-peptide fibrinogen receptor antagonist on human platelets in vitro. Thromb Haemostas 1993; 69(6): 559.
7. Humphries RG, Tomlinson W, Ingall AH, Cage PA, Leff P. FPL 66096: a novel, highly potent and selective antagonist at P2T-purinoceptors. Br J Pharmacol 1994; 113: 1057-63.
8. Fujimura K, Fujimoto T, Takemoto M, Oda K, shimomura T, Maehama S, Kurumoto A. Analysis of platelet cytoskeleton assembly during platelet activation in Hermansky-Pudlak syndrome and thrombasthenia. Thromb Haemostas 1990; 63: 103-11.
9. Lefebvre P, White JG, Krumwiede MD, Cohen I. Role of actin in platelet function. Eur J Cell Biol 1993; 62: 194-204.
10. 3 (GpIIb-IIIa) requires a functional actin cytoskeleton. Arterio Thromb Vasc Biol 1995; 15: 1466-73.
11. Legrand C, Dubernard V, Rabhi-Sabile S, Morandi da Silva V. Functional and clinical significance of thrombospondin. Platelets 1997; 8: 211-23.